Empagliflozin is a highly selective SGLT2 inhibitor with well-documented cardiovascular and renoprotective outcomes data, used for type 2 diabetes and now also approved in heart failure with or without reduced ejection fraction. Simson Pharma's Empagliflozin reference standard and impurities support stability-indicating method development across this high-priority therapeutic class.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Empagliflozin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.